Global Bioenergies Reduces Its Losses
GLOBAL BIOENERGIES REDUCES ITS
LOSSES
Evry (France), 17 October 2019
– Publication of half-year financial statements as at 30
June 2019, audited and adopted by the Board of Directors at today’s
meeting.
The report for the first half of 2019 is
available on the Global Bioenergies website, under the heading
“Investors/Regulated Information”.
·Group Profit & Loss Account as at
30 June 2019
|
|
|
|
€ thousands |
from
01/01/19 |
from
01/01/18 |
from 01/01/17 |
CONSOLIDATED FINANCIAL STATEMENTS |
to
30/06/19 |
to
30/06/18 |
to 30/06/17 |
|
6
months |
6 months |
6 months |
|
|
|
|
|
|
|
|
Operating income |
1,427 |
746 |
1,209 |
Operating expenses |
8,974 |
9,309 |
8,655 |
Operating profit (loss) |
-7,546 |
-8,564 |
-7,446 |
|
|
|
|
EBITDA |
-5,719 |
-6,601 |
-6,315 |
|
|
|
|
Financial profit (loss) |
-154 |
-323 |
-368 |
Extraordinary profit (loss) |
119 |
80 |
15 |
|
|
|
|
Income tax |
NA* |
NA* |
NA* |
|
|
|
|
Net profit (loss) |
-7,580 |
-8,807 |
-7,799 |
* Note: By convention, the Group does not record
a research tax credit in its half-year financial statements at the
end of June.
In the first half of 2019 losses are down by
over €1.2 million compared with the first half of 2018. The
industrialisation efforts initiated in 2014 have resulted in
increased expenses by the Group which is reflected in the net
losses in the first half of each year: -€3.9 million in 2014, -€6.1
million in 2015, -€6.7 million in 2016, -€7.8 million in 2017 and
then -€8.8 million in 2018. The €7.6 million loss recorded in the
first half of 2019 is evidence of a reversal of this trend.
Operating income is mainly driven by the five
European grants awarded to Global Bioenergies in 2017 and 2018
totalling €12 million. The first half of 2019 benefited from the
effect of a “full half-year” compared with the two previous
reporting periods in which projects were launched.
Operating expenses are beginning to decrease and
remain impacted by the amortisation of the Leuna demo plant (€1.5
million in this half-year). As a reminder, this demo plant is being
amortised over a 4-year period ending in the first half of
2021.
·Group Balance Sheet as at 30 June
2019
Assets (€ thousands) |
30/06/19 |
31/12/18 |
|
Liabilities (€ thousands) |
30/06/19 |
31/12/18 |
|
|
|
|
|
|
|
Intangible assets |
1,223 |
1,228 |
|
Capital |
436 |
254 |
Assets |
6,017 |
7,778 |
|
Share premium |
90,358 |
74,207 |
Financial assets |
1,065 |
1,061 |
|
Retained earnings |
-68,563 |
-54,926 |
|
|
|
|
Profit (loss) |
-7,580 |
-13,637 |
|
|
|
|
Equipment subsidies |
298 |
383 |
|
|
|
|
|
|
|
NON-CURRENT ASSETS |
8,305 |
10,067 |
|
EQUITY |
14,949 |
6,280 |
|
|
|
|
|
|
|
|
|
|
|
PROVISIONS |
88 |
66 |
|
|
|
|
|
|
|
Inventories + Receivables |
3,962 |
4,262 |
|
Conditional advances and loans |
8,348 |
9,356 |
Cash and marketable securities |
20,777 |
10,756 |
|
Trade payables and related accounts |
2,851 |
3,356 |
Prepaid expenses |
331 |
352 |
|
Other debts and deferred income |
7,138 |
6,379 |
|
|
|
|
|
|
|
CURRENT ASSETS |
25,069 |
15,370 |
|
PAYABLES & DEF. INCOME |
18,338 |
19,090 |
|
|
|
|
|
|
|
TOTAL ASSETS |
33,374 |
25,436 |
|
TOTAL LIABILITIES |
33,374 |
25,436 |
An analysis of the consolidated balance sheet
reveals the following main changes:
- reduction in non-current assets resulting from
the amortisation of the Leuna demo plant;
- increase in cash position, which reaches €20.8
million at 30 June 2019;
- reduction in “payables and deferred income”
items, still heavily impacted by the European grants cashed in 2017
and 2018 upon initiation of the projects, which amounts still
exceed the related expenses at 30 June 2019 and are therefore
recorded under “deferred income” for a total of €5.7 million.
·Global Bioenergies Group cash flows as
at 30 June 2019
CASH-FLOW (€ thousands) |
H1 2019 |
2018 |
2017 |
|
|
|
|
Operating cash-flow |
-5,195 |
-7,418 |
-9,066 |
Net profit (loss) |
-7,580 |
-13,637 |
-14,253 |
Amortisation |
1,808 |
3,457 |
2,857 |
Impact of the change in WCR |
577 |
2,762 |
2,330 |
|
|
|
|
Investing cash-flow |
-66 |
-974 |
-2,022 |
Financing cash-flow |
15,408 |
5,259 |
16,143 |
Capital increase net of related expenses booked on the issue
premium |
16,334 |
6,070 |
17,153 |
Equipment subsidies |
- |
- |
289 |
Advances or loans received |
- |
1,384 |
300 |
Advances or loans repaid |
932 |
2,279 |
1,612 |
Contribution shareholder current accounts |
6 |
84 |
12 |
|
|
|
|
The cash flow statement mainly reflects the
capital increase of €16.9 million last June, of which €590 thousand
corresponding to related expenses booked on the issue premium.
·Highlights of the first half of 2019
and recent events
Beginning of a shift towards cosmetics
The first half of 2019 was characterised by the
beginning of a shift towards cosmetics. Although potential market
opportunities in this industry had long been identified - as shown
by the partnership entered into with L’Oréal in 2016 - recent
changes have, on the one hand, increased the depth of this market
which, until now, had been considered relatively thin, and, on the
other, bolstered the idea that the cosmetics industry could offer
significantly higher prices for isobutene derivatives than those
identified in the fuel sector. These changes are related to
consumer demand for natural, more environmentally-friendly
products. This quest for naturalness, which can be seen across the
board in many markets, is particularly visible in the area of
cosmetics where there is even a sense of urgency since the sector
is subject to new regulations limiting the use of certain
fossil-based products. The fact that L’Oréal, world leader in
cosmetics, is now the Company’s biggest shareholder is an
undeniable illustration of these changes.
Fundraising
A capital increase operation through a public
offering and removal of the preferential subscription rights was
launched in June raising a total of almost €17 million. This
operation resulted in 3,639,475 new shares being issued, with an
investment of €7 million by the BOLD Business Opportunities for
L’Oréal Development fund and that of €1.4 million by CM-CIC,
sitting at the Board of Directors of the Company and which already
had an 8.3% share of its equity.
A new milestone achieved in the ISOPROD
project
Global Bioenergies and IBN-One achieved a
milestone in July as part of the ISOPROD project funded by ADEME.
As a reminder, this project focuses on the emergence of the first
operating plant for the Global Bioenergies process. Achieving this
milestone is evidence of the progress made on this project and will
soon result in the payment of €3.1 million to the Group in the form
of repayable advances.
Samuel Dubruque, Chief Financial Officer of
Global Bioenergies, said: “We will continue to improve the Group’s
net result in the coming half-years.”
Marc Delcourt, co-founder and Chief Executive
Officer of Global Bioenergies, concluded: “Since the capital
increase last June, Global Bioenergies’s stock has been under
pressure: currently our market valuation is close to our cash in
hand. However, the development of our process has afforded us
universal recognition in the synthetic biology sector and the
IBN-One plant project is one of the most innovative in this
emerging industrial sector worldwide.”
About GLOBAL BIOENERGIES
Global Bioenergies is the only company in the
world to have developed a conversion process for renewable
resources (residual sugars, agricultural and forestry waste) into
isobutene, one of the petrochemical building blocks that can be
converted into ingredients for cosmetics, petrol, kerosene, LPG and
plastics. Global Bioenergies continues to improve the performance
of its process, conducts trials on its demo plant in Germany and is
preparing the first full-sized plant in a Joint‐Venture with
Cristal Union. Global Bioenergies is listed on Euronext Growth in
Paris (FR0011052257 – ALGBE).
Stay informed! Subscribe to our newsfeed
on www.global-bioenergies.com
Follow us on Twitter:
@GlobalBioenergi
Contact
GLOBAL BIOENERGIESSamuel
DubruqueCFOPhone : 01 64 98 20 50invest@global-bioenergies.com
- GLOBAL BIOENERGIES REDUCES ITS LOSSES
Global Bioenergies (EU:ALGBE)
Historical Stock Chart
From Apr 2024 to May 2024
Global Bioenergies (EU:ALGBE)
Historical Stock Chart
From May 2023 to May 2024